New Hope, Long Wait: A Breakthrough Cancer Therapy Is Coming to Canada—Eventually

MONTREAL, QC – June 10, 2026 – For Canadians battling high-risk blood cancers, a new announcement offers a significant, if distant, beacon of hope. Montreal-based ExCellThera Inc. has granted specialty pharmaceutical company Medexus the exclusive Canadian rights to commercialize Zemcelpro®, a revolutionary cell therapy that has already received conditional approval in Europe.

The deal represents a homecoming for a Canadian-born innovation and a critical step in bringing a life-saving treatment to patients who have exhausted all other options. Yet, behind the corporate handshakes and promising clinical data lies a more complex reality: the therapy is not expected to be available here before 2028, a timeline that lays bare the challenging path from scientific breakthrough to a patient's bedside.

The Promise of a Lifeline

For many patients with aggressive hematological malignancies like acute leukemias and myelodysplasias, an allogeneic hematopoietic stem cell transplant (HSCT)—a procedure that replaces a patient's diseased bone marrow with a donor's healthy stem cells—is the only potential cure. The problem, however, is finding a match. Thousands of patients each year are unable to find a suitable donor, leaving them with grim prognoses.

Zemcelpro® directly confronts this critical unmet need. The therapy utilizes stem cells from umbilical cord blood, a source that often goes unused for adult transplants because the cell count is too low. Using its proprietary UM171 molecule, ExCellThera’s technology can expand the number of functional stem cells from a single cord blood unit, making it a viable, life-saving option for a much broader pool of patients.

"These agreements with Medexus represent today an important milestone and reflect our continued commitment to advancing Zemcelpro® for patients with significant unmet medical needs," said David Millette, CEO of Cordex Biologics, ExCellThera's subsidiary. He emphasized the therapy's potential to "meaningfully improve access to innovative therapies for Canadian patients."

The data behind this optimism is compelling. The European Commission granted its conditional approval based on studies where 84% of patients achieved successful engraftment of donor cells. More strikingly, Phase 2 trial data for patients with high-risk cancers—a group with notoriously poor outcomes—showed a 67% overall survival rate at 24 months. For those in the fight of their lives, these are not just statistics; they are the tangible possibility of a future.

The Science of Second Chances

At the heart of this medical advance is a story of Canadian innovation. The UM171 molecule was first developed at the Université de Montréal before being spun out into ExCellThera in 2015. Zemcelpro®, also known as UM171 Cell Therapy, is a personalized product composed of two parts from the same cord blood unit: a portion of stem cells expanded with the UM171 molecule, and a portion of unexpanded cells. This dual-component approach is designed to accelerate the rebuilding of a patient's blood and immune system, reducing the dangerous window of vulnerability after a transplant.

The therapy's potential has been recognized by regulators globally. It has received a host of special designations from both the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), including Orphan Drug, Regenerative Medicine Advanced Therapy (RMAT), and Priority Medicines (PRIME) status. These are not mere accolades; they are official acknowledgements that the therapy represents a potentially significant leap forward over existing options and serves a patient population in desperate need.

The Long Road to the Patient’s Bedside

While the science is moving quickly, the logistics of healthcare systems move at a different pace. The partnership with Medexus is a calculated strategic play. Medexus has deep experience in the Canadian hematology and oncology market, already marketing Trecondi®, a drug used to prepare patients for the very type of transplant that Zemcelpro® facilitates. Their expertise and existing infrastructure are crucial for navigating the complex path to market.

That path, however, is long. The 2028 target for Canadian availability is a sober reminder of the regulatory and logistical hurdles involved. While Zemcelpro® has cleared the bar for conditional approval in Europe, it must start the process anew with Health Canada. Medexus will need to submit a New Drug Submission, a process that can take years. While accelerated pathways exist for promising therapies, Canada has a track record of lagging behind Europe and the U.S. in drug approvals, a systemic delay that can be a matter of life and death for patients with aggressive diseases.

This agreement is part of ExCellThera's larger global commercialization strategy. Having secured a foothold in Europe and now Canada, the company is actively pursuing partnerships in other markets. For a biotech firm, such deals are essential. They validate the technology, secure crucial revenue through milestone payments and royalties, and fund the next wave of research, including a pivotal Phase 3 trial and investigations into using the therapy for pediatric patients and other diseases.

"We believe there is substantial global interest in innovative therapies that address persistent unmet needs," Millette stated, underscoring the dual mission of bringing life-changing therapies to patients while "creating long-term value for our stakeholders." It is within this intersection of patient hope and shareholder value that the future of modern medicine is being forged, one complex licensing agreement at a time.